Peru remains on a watch list at the Office of the United States Trade Representative (USTR), due to the country’s failure to control medicine counterfeiting and patent infringement.

According to Peru21, Peru was one of 40 countries that were analyzed by the USTRs ‘Special 301’ report.

The daily said the country’s recent efforts to criminalize the sale of counterfeit medicines were highlighted in the report.

However, the U.S. expressed concern about the widespread availability of counterfeit and patent-infringement medicine that are produced in the country.

"Further work is needed to coordinate efforts to implement this law and carry out prosecutions," the agency said.

The USTR said additional resources should be allocated for the upholding of intellectual property rights, and said coordination between government agencies should be improved.

---

MORE NEWS

• Peru’s Toledo says controversial house purchase was funded by loan
• Peru’s Macho Train to restart service
• Peru: Arequipa airport closed over bomb threat
• Peru’s Kuczynski: ‘There are clear signs the economy is slowing’
• Peru’s Humala speaks of regional integration at Pacific Alliance summit